Johnson & Johnson (NYSE:JNJ – Get Free Report) EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Johnson & Johnson Price Performance
Shares of NYSE JNJ traded up $2.26 during midday trading on Friday, reaching $285.78. 6,279,519 shares of the stock traded hands, compared to its average volume of 7,472,752. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a market capitalization of $687.95 billion, a PE ratio of 43.30, a P/E/G ratio of 2.80 and a beta of 0.22. Johnson & Johnson has a one year low of $193.55 and a one year high of $288.11. The company’s 50 day moving average is $266.97 and its 200 day moving average is $249.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.
Institutional Trading of Johnson & Johnson
Institutional investors have recently bought and sold shares of the stock. Outlook Capital Management LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at about $28,000. Matrix Trust Co raised its position in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares during the period. Navigoe LLC raised its position in Johnson & Johnson by 60.4% in the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after purchasing an additional 55 shares during the period. Montgomery Financial Services LLC bought a new stake in Johnson & Johnson in the second quarter worth about $43,000. Finally, Hanseatic Management Services Inc. bought a new stake in Johnson & Johnson in the third quarter worth about $52,000. 69.55% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. Royal Bank Of Canada dropped their price target on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. Finally, Sanford C. Bernstein set a $270.00 price objective on Johnson & Johnson in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.92.
Read Our Latest Stock Report on Johnson & Johnson
Trending Headlines about Johnson & Johnson
Investors following JNJ have been watching these headlines:
- Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
- Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson
- Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
